Tango Therapeutics Net Worth
Tango Therapeutics Net Worth Breakdown | TNGX |
Tango Therapeutics Net Worth Analysis
Tango Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tango Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tango Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tango Therapeutics' net worth analysis. One common approach is to calculate Tango Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tango Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tango Therapeutics' net worth. This approach calculates the present value of Tango Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tango Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tango Therapeutics' net worth. This involves comparing Tango Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tango Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Tango Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tango Therapeutics' net worth research are outlined below:
| Tango Therapeutics generated a negative expected return over the last 90 days | |
| Tango Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 36.53 M. Net Loss for the year was (101.74 M) with loss before overhead, payroll, taxes, and interest of (81.05 M). | |
| Tango Therapeutics currently holds about 416.36 M in cash with (117.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tango Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference |
Tango Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tango Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tango Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Tango Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tango Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tango Therapeutics backward and forwards among themselves. Tango Therapeutics' institutional investor refers to the entity that pools money to purchase Tango Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Balyasny Asset Management Llc | 2024-09-30 | 2.7 M | State Street Corp | 2024-09-30 | 2.3 M | Adage Capital Partners Gp Llc | 2024-09-30 | 2.3 M | Deerfield Management Co | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Casdin Capital, Llc | 2024-09-30 | 1.2 M | Baker Bros Advisors Lp | 2024-09-30 | 750 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 708.4 K | Bessemer Group Inc | 2024-09-30 | 708.4 K | Trv Gp Iv, Llc | 2024-09-30 | 16.9 M | Ecor1 Capital, Llc | 2024-09-30 | 13.3 M |
Follow Tango Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 417.86 M.Market Cap |
|
Project Tango Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.40) | (0.42) |
When accessing Tango Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tango Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tango Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tango Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tango Therapeutics. Check Tango Therapeutics' Beneish M Score to see the likelihood of Tango Therapeutics' management manipulating its earnings.
Evaluate Tango Therapeutics' management efficiency
Tango Therapeutics has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4879) %, meaning that it created substantial loss on money invested by shareholders. Tango Therapeutics' management efficiency ratios could be used to measure how well Tango Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.34 in 2024. At this time, Tango Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.15 in 2024, whereas Total Assets are likely to drop slightly above 352.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.68 | 2.10 | |
| Tangible Book Value Per Share | 2.68 | 2.14 | |
| Enterprise Value Over EBITDA | (8.13) | (8.54) | |
| Price Book Value Ratio | 3.70 | 6.45 | |
| Enterprise Value Multiple | (8.13) | (8.54) | |
| Price Fair Value | 3.70 | 6.45 | |
| Enterprise Value | 908.8 M | 954.2 M |
At Tango Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 3.7389 | Revenue 43.4 M | Quarterly Revenue Growth 0.082 | Revenue Per Share 0.402 | Return On Equity (0.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tango Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tango Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tango Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tango Therapeutics Corporate Filings
13A | 20th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 22nd of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Tango Therapeutics Earnings per Share Projection vs Actual
Tango Therapeutics Corporate Management
| MD Kaelin | Founder Board | Profile | |
| Antoni MD | Founder Board | Profile | |
| Daniella CPA | Chief Officer | Profile | |
| Alan Huang | Chief Officer | Profile | |
| Levi MD | Founder | Profile | |
| JD Esq | Chief Counsel | Profile |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.